ADMA Biologics saw no growth in patent filings and highest growth of 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of ADMA Biologics’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
ADMA Biologics has been focused on protecting inventions in Israel(IL) with one publication in Q2 2024
The Israel(IL) Patent Office dominates the patent grants with nearly 100% of grants. The Israel(IL) patent Office are among the top ten patent offices where ADMA Biologics is filings its patents. Among the top granted patent authorities, ADMA Biologics has 100% of its grants in Israel(IL).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for ADMA Biologics
Sinusitis related patents lead ADMA Biologics portfolio followed by pneumonia, and bronchitis
ADMA Biologics has highest number of patents in sinusitis followed by pneumonia, bronchitis.
For comprehensive analysis of ADMA Biologics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
